Wells Fargo lowered the firm’s price target on Danaher (DHR) to $240 from $280 and keeps an Equal Weight rating on the shares. While Danaher’s Bioprocess trends align with the firm’s view of a broader market recovery, the Life Science outlook is incrementally softer, Wells says. 2025 guide may be conservative, but at 30-turns EPS, the firm sees a balanced risk/reward.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher price target lowered to $265 from $285 at Citi
- Danaher price target lowered to $240 from $275 at Barclays
- Danaher Corporation Reports Steady 2024 Financial Performance
- Danaher Corporation Reports Earnings: Did it Beat Estimate Forecasts?
- Danaher price target lowered to $240 from $250 at Goldman Sachs